Massachusetts-based women’s health devices maker Hologic (NSDQ:HOLX) got some attention on Wall Street after releasing a preliminary earnings report predicting that it would meet or exceed expectations for the 3rd quarter.
Hologic announced that it expects to beat its 34¢ guidance as sales of its Dimensions 3D breast tomosynthesis systems are ramping up more quickly than anticipated.
The device maker has already attained more 45% of its 2-year goal of installing between 500 and 700 of the new 3D systems in the U.S., and expects to reach 60% of the goal by the end of the year.
Hologic also provided updates on its $3.7 billion acquisition of Gen-Probe, which is expected to close August 1.
"We are making great progress toward completing the acquisition of Gen-Probe, which will strengthen our growing diagnostics portfolio and advance our presence in the overall molecular diagnostics market," Hologic president & CEO Rob Cascella said in prepared remarks. "The global outlook for diagnostics is compelling and as a combined company we expect to capitalize on the significant opportunities in the market."
Natus to lay off 8% following Nicolet acquisition
Natus Medical (NSDQ:BABY) plans to lay off 95 workers following its $58 million acquisition of Nicolet, which represents 8% of the combined workforce of the pair of companies. Read more
Mako Surgical lowers guidance
Mako Surgical (NSDQ:MAKO) watched its shares plunge this week after the company lowered its guidance on 2012 sales of its RIO surgical robots. MAKO shares dove 40% on Tuesday, July 10, to close at $14.01, compared with a closing price of $24.61 the night before. Read more
Echo Therapeutics signs exclusive agreement for Prelude SkinPrep
Echo Therapeutics (NSDQ:ECTE) signed an exclusive distribution agreement with Ferndale Pharma Group for right to sell the Prelude SkinPrep system in the U.S., Canada, Mexico and the U.K. Read more
Teleflex opens new plant in Mississippi
Limerick, Pa.-based Teleflex (NYSE:TFX) signed a lease on a new 630,000-square-foot facility in Olive Branch, Miss. Read more
- Ancor Capital and Merit Capital acquire Canada-based Uplift Technologies
- Luminex nabs molecular diagnostics maker GenturaDx
- Customer relations company Merkle buys mobile health app maker 5th Finger
- Sorin Group puts $8M into mitral valve tech maker Cardiosolutions
Abbott hits 52-week high
Abbott (NYSE:ABT) notched new high-water mark this week, with shares trading for up to $66.30 on Tuesday, July 10, before closing at $64.67.
- Abiomed (NSDQ:ABMD): Zacks Investment Research downgrades from "outperform" to "neutral"
- AthenaHealth (NSDQ:ATHN): ISI Group initiates coverage at "overweight" with $94 price target
- Becton Dickinson & Co. (NYSE:BDX): Canaccord Genuity reiterates "hold" rating
- Bruker Corp. (NSDQ:BRKR) : Cantor Fitzgerald initiates coverage at "buy" with $16 price target.
- Bruker Corp. (NSDQ:BRKR) : ISI Group initiate coverage with "market weight" rating and a price target of $14.50
- Cardinal Health (NYSE:CAH): J.P. Morgan reiterates "overweight" rating
- Cerner (NSDQ:CERN): ISI Group initiates coverage at "market weight" with $87 price target
- C.R. Bard (NYSE:BCR): Piper Jaffray raises price target from $92 to $102, maintains "neutral" rating
- Danaher (NYSE:DHR): Morgan Stanley reiterates "overweight" rating a price target of $60; ISI Group initiated its coverage "market weight" rating and a price target of $56
- Edwards Lifesciences (NYSE:EW): Piper Jaffray reiterates "overweight" rating, raises price target from $90 to $118; Credit Suisse downgrades from "outperform" to "neutral", raises price target from $99 to $110
- Henry Schein (NSDQ:HSIC): ISI Group initiates coverage at "underweight" with $74.50 price target
- Hologic (NSDQ:HOLX): ISI Group initiated coverage with "overweight" rating and a price target of $21; Leerink maintains "outperform" rating; ISI Group initiates at "overweight" with $21 price target; Canaccord Genuity reaffirms "buy" rating
- Insulet (NSDQ:PODD): Shares under pressure after CL King initiates coverage with a "sell" rating and downside $18 price target
- Intuitive Surgical (NSDQ:ISRG): Needham & Company maintains a "hold" with a price target of $535.00; Needham & Co. maintains "hold" rating, $535 price target
- Luminex (NSDQ:LMNX): JP Morgan reiterates "underweight" rating reduces price target from $18 to $17
- McKesson (NYSE:MCK): ISI Group initiates coverage at "overweight" with $104 price target
- Medtronic (NYSE:MDT): Trefis initiates coverage with $41 price target
- Sirona Dental Systems (NSDQ:SIRO): Baird upgrades from "neutral" to "outperform" with $53 price target
- Thoratec (NSDQ:THOR): Goldman Sachs raises rating from "neutral" to "buy", increases price target from $34 to $45
- Varian Medical (NYSE:VAR): Citigroup reiterates its "neutral" rating, reduces price target from $67 to $63
- Volcano (NSDQ:VOLC): Credit Suisse initiates with "outperform" rating and a price target of $36